2025-09-09 - Analysis Report
Okay, here's an analysis of Natera (NTRA) based on the data you provided, presented with key numbers first, followed by analysis, and summarized in English.

## NTRA Stock Analysis

**Ticker:** NTRA (Natera Inc.)

**Company Overview:** Natera is a genetic testing company focused on non-invasive prenatal testing (NIPT) and cancer diagnostics.

### 1. Performance vs. S&P 500 (VOO)

*   **NTRA Cumulative Return:** 159.01%
*   **VOO Cumulative Return:** 97.02%
*   **Absolute Divergence (NTRA - VOO):** 57.4%
*   **Divergence Range (Max: 631.9, Min: -39.3)**
*   **Relative Divergence:** 14.4

**Analysis:** NTRA has significantly outperformed the S&P 500 (VOO) over the period considered. The current divergence of 57.4% indicates a substantial lead. The relative divergence of 14.4 suggests that the current outperformance is in the lower range of its historical divergence pattern compared to S&P500.

### 2. Alpha, Beta Analysis

| Year       | CAGR     | MDD      | Alpha    | Beta   | Cap(B) |
|------------|----------|----------|----------|--------|--------|
| 2015-2017  | -6.0%    | 62.4%    | -31.0%   | -0.1   | 1.2    |
| 2016-2018  | 29.0%    | 80.1%    | 13.0%    | 0.1    | 1.9    |
| 2017-2019  | 159.0%   | 80.1%    | 132.0%   | 0.9    | 4.6    |
| 2018-2020  | 530.0%   | 80.1%    | 511.0%   | 0.2    | 13.6   |
| 2019-2021  | 355.0%   | 62.9%    | 308.0%   | 0.1    | 12.8   |
| 2020-2022  | -119.0%  | 62.9%    | -121.0%  | 0.1    | 5.5    |
| 2021-2023  | -482.0%  | 69.9%    | -499.0%  | 1.1    | 8.6    |
| 2022-2024  | -75.0%   | 70.6%    | -100.0%  | 1.1    | 21.6   |
| 2023-2025  | 108.0%   | 76.1%    | 56.0%    | 0.8    | 23.0   |

**Analysis:**

*   **CAGR:** NTRA's CAGR exhibits significant volatility, ranging from -482.0% to 530.0%, indicating periods of both extreme growth and sharp decline.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, typically exceeding 60%, demonstrating significant risk and volatility.
*   **Alpha:** Alpha values fluctuate dramatically, reflecting NTRA's performance relative to the market. High positive alpha indicates significant outperformance, while negative alpha indicates underperformance.
*   **Beta:** Beta values vary, indicating varying degrees of correlation with the market. The range of 0.1 to 1.1 shows that NTRA's price is not always tightly correlated with the market.
*   **Capitalization:** Market capitalization shows a gradual increase, indicating increasing investor interest and valuation over time.

### 3. Recent Price Action

*   **Current Price:** 168.02
*   **Last Market Data:** {'price': 167.39, 'previousClose': 168.02, 'change': -0.37}
*   **5-Day Moving Average:** 167.91
*   **20-Day Moving Average:** 162.80
*   **60-Day Moving Average:** 156.76

**Analysis:**

*   The slight price decrease in the last market data indicates a minor pullback.
*   The price is above all three moving averages, suggesting an upward trend, especially considering the 20-day and 60-day moving averages.

### 4. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 59.02
*   **PPO:** 0.21
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Delta_Previous_Relative_Divergence (20-day):** 0.0 (Neutral)
*   **Expected Return:** 95.2%

**Analysis:**

*   **MRI:** The low MRI suggests a relatively stable market environment for the stock currently.
*   **RSI:** The RSI is approaching overbought territory (above 70), suggesting the stock may be due for a minor correction, but it's not yet at an extreme level.
*   **PPO:** A positive PPO indicates that the shorter-term moving average is above the longer-term moving average, confirming the upward trend.
*   **Hybrid Signal:** This signal advises a partial buy, while indicating caution due to the MRI (slightly elevated).
*   **Delta_Previous_Relative_Divergence:** The value indicates no recent change in relative divergence.
*   **Expected Return:** A high expected return suggests significant potential for long-term outperformance compared to the S&P 500.

### 5. Recent News & Significant Events

*   **ARCHER Trial:** Potential impact on valuation after Signatera milestone.
*   **Liquid Biopsy Market:** Industry forecast to 2030 featuring strategic analysis of Natera.
*   **Intellectual Property Litigation:** Update on litigation with NeoGenomics.
*   **Analyst Opinions:**
    *   Consensus: Strong Buy
    *   Mean: 1.45 (~Strong Buy)
    *   Target Price (avg/high/low): 198.45 / 268.00 / 37.00
*   **Stock Down:** Why Natera (NTRA) Stock Is Down Today
*   **Stock Up:** Why Is NeoGenomics (NEO) Stock Soaring Today

**Analysis:**

*   The news is mixed. The ARCHER trial and liquid biopsy market reports are potentially positive catalysts. The intellectual property litigation is an ongoing risk. The analyst consensus is strongly positive, with a high average target price. The news of the stock being down is a negative factor, while NeoGenomics stock soaring on the same day implies that the market might be shifting towards its competitor.

### 6. Earnings Analysis

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-08-08 | -0.74 | 0.55 B$   |
| 2025-05-09 | -0.5  | 0.50 B$   |
| 2024-11-12 | -0.26 | 0.44 B$   |
| 2024-08-09 | -0.3  | 0.41 B$   |
| 2025-08-08 | -0.3  | 0.41 B$   |

**Analysis:**

*   The company is not yet profitable, with negative EPS values. However, there is a general trend of increasing revenue, which is a positive sign. The most recent EPS figure has increased.

### 7. Financial Information

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | $0.55B  | 63.41%        |
| 2025-03-31   | $0.50B  | 63.12%        |
| 2024-12-31   | $0.48B  | 62.94%        |
| 2024-09-30   | $0.44B  | 61.79%        |
| 2024-06-30   | $0.41B  | 58.83%        |

| Quarter      | Equity  | ROE      |
|--------------|---------|----------|
| 2025-06-30   | $1.25B  | -8.10%   |
| 2025-03-31   | $1.24B  | -5.40%   |
| 2024-12-31   | $1.20B  | -4.50%   |
| 2024-09-30   | $0.88B  | -3.60%   |
| 2024-06-30   | $0.84B  | -4.48%   |

**Analysis:**

*   **Revenue:** Revenue is consistently growing, indicating strong demand for Natera's products and services.
*   **Profit Margin:** Profit margins are high and relatively stable, suggesting efficient operations.
*   **Equity:** Equity is increasing, demonstrating a growing asset base.
*   **ROE:** While still negative, the Return on Equity (ROE) is trending towards improvement, indicating increasing profitability as the company matures.

### 8. Overall Summary

Natera (NTRA) is a high-growth, high-volatility stock with significant outperformance compared to the S&P 500. The company is not yet profitable, but revenue is growing strongly, and profit margins are healthy. Analyst consensus is strongly positive. Recent news is mixed, with both potential positive catalysts and ongoing risks. The technical indicators suggest a stock in an upward trend, potentially approaching overbought territory. The high expected return indicates significant long-term potential.

**In summary, NTRA presents a compelling investment opportunity for investors with a high-risk tolerance and a long-term investment horizon.**
